ERBB2 and cancer: This was in agreement with many clinical and commercial laboratories choosing 10% or even 20% positive tumour cells as the cut off value for defining oestrogen receptor (ER), progesterone receptors (PR), and HER2 positivity in cancer tissues [36,72,73].